Article

AAV-mediated Expression of a Novel Conformational Anti-Aggregated α-Synuclein Antibody Prolongs Survival in a Genetic Model of α-Synucleinopathies

2022-12-01

Abstract excerpt

Prion-like transmission of pathology in α-synucleinopathies like Parkinson’s disease or multiple system atrophy is increasingly recognized as one potential mechanism to address disease progression. Active and passive immunotherapies targeting insoluble, aggregated α-synuclein are already being actively explored in the clinic with mixed outcomes so far. Here, we report the identification of 306C7B3, a highly select...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ede4172b-6bea-5bc1-af50-19ed95748fd3
DOI: 10.1101/2022.11.30.518485

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AAV-mediated Expression of a Novel Conformational Anti-Aggregated α-Synuclein Antibody Prolongs Survival in a Genetic Model of α-SynucleinopathiesDOI 10.1101/2022.11.30.518485Read

Monoclonal antibodies targeting cytotoxic α-synuclein oligomers: molecular properties and diagnostic potentialSemantic proximity Read

A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathiesSemantic proximity Read

Virally encoded single-chain antibody fragments targeting alpha-synuclein protect against motor impairments and neuropathology in a mouse model of synucleinopathySemantic proximity Read

Reconsidering α-Synuclein inclusion pathology in neurons, mice, and humans with an antibody sensing NAC engagement during α-Synuclein amyloid conversionSemantic proximity Read

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomersSemantic proximity Read

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s diseaseSemantic proximity Read

Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in VivoSemantic proximity Read

A Versatile AAV-TH-SNCA Model to Study Early α-Synuclein Pathology and InterventionSemantic proximity Read

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit <i>in‐vitro</i> seeded aggregation and toxicitySemantic proximity Read

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody FragmentsSemantic proximity Read

Intranigral injection of Alpha-Synuclein pre-formed fibrils leads to BBB compromise and Bilateral Dopaminergic Neurodegeneration in A53T Alpha-Synuclein transgenic miceSemantic proximity Read

An scFv Intrabody against the Nonamyloid Component of α-Synuclein Reduces Intracellular Aggregation and ToxicitySemantic proximity Read